Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. - Wikidata - awgldk - TriplyDB

Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.

Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.

http://www.wikidata.org/entity/Q34726376

about

Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis.Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study Extracts of Coreopsis tinctoria Nutt. Flower Exhibit Antidiabetic Effects via the Inhibition of α-Glucosidase Activity.Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.Dapagliflozin: a review of its use in patients with type 2 diabetes.The effect of SGLT2 inhibitors on cardiovascular events and renal function.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).

P2860

Q26775823-E773C2C5-4786-46D9-9B5F-33EB82FE78CA Q26782225-B08F0A4E-ECD3-48AF-97B0-B6BAA9777338 Q31117903-0CA7DEBF-6312-4EF7-BA57-01680C226C5D Q33614337-39E13A70-5878-43C3-B5E5-92C9AD676954 Q33871321-9B5DAFFA-8D9E-4B9F-B5AC-3A715C2EE980 Q33882438-7A631ED5-1911-4EBB-9E9A-D3D8A008215B Q36327116-32955F4A-573B-4426-8B93-8FC9D0B9DC47 Q36532294-7B9D39F6-6F16-4B38-83B2-88DB2BC8138F Q36756191-7CCD3415-5F69-4B26-A536-B678ADCDC6D9 Q36760425-367F3706-3285-47C0-9FED-8EF32728E857 Q37060860-BAD313B6-B6A1-49A7-AA69-682FA550E5E0 Q37302700-EBB17A3C-F7C2-4059-986E-2D3838346FF2 Q38267346-B193B5A3-C34C-49B0-BBF3-BB659B9C774F Q38614488-574EE07A-361A-4FAC-BAF9-2392454903E9 Q38645792-1B5E6AB4-D5C6-4330-A6C2-D8424FFED76D Q38821464-C9A7D6C2-0A11-4641-BAC0-3C7B8EB95FEC Q38824557-97419EC1-7498-4D1A-9278-69AE5FAFF387 Q40091881-1FD2B932-D156-489A-9AE4-DAB1917B9BBB Q40405896-EC6FEE8D-28A0-47B0-B7FE-9A6FBC9733AD Q41073983-3BEFDCEC-84AC-4671-A94E-EF9AE61C9167 Q42082791-9BD3324E-9E68-48CB-B90B-D54A3445C7AE Q47148933-22462CDC-430C-4068-9463-05F26EB3757E Q48234943-1E80E340-A6E3-47A6-B150-0A51E2EB7C2A Q48274765-57F2F1BA-880C-4F12-8C48-DDBCB3A68B7C Q51045694-D04ADF57-9666-45AC-ABF6-3680EDACF03B Q51246665-312A4F55-C2CA-4EB8-95A9-D30558D1D404 Q51731100-9C8DC2FD-9107-4AE8-8AA1-BF4AC42C24FA Q51744128-F7642829-6591-47A5-A8EA-71375016CD6E

P2860

Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.

http://www.wikidata.org/entity/Q34726376

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@ast

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@en

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@nl

type

label

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@ast

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@en

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@nl

prefLabel

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@ast

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@en

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@nl

P1433

Q34726376-494108E3-0C4B-440A-B375-617B212591AA

P1476

Q34726376-2F2183FA-A492-47C4-8D10-0585E66303B9

P2093

Q34726376-08B51B64-675D-4AFF-9A4B-B7E6BFE77082

Q34726376-3C1CA4C4-BE43-48C2-8EE3-4C2F65505914

Q34726376-5943C94B-EFD2-45A8-A317-1430884346EE

Q34726376-6EACF3E8-1AD3-4EDA-9DFD-195D7A71BD56

Q34726376-77581618-4146-421D-A0E6-B6198FB785C9

Q34726376-8839326B-5C88-4A06-8C23-854629642E8C

Q34726376-B0ABC804-A805-46EC-A306-09C2BF8B6E76

Q34726376-CE45A867-3C05-4C5A-B7E6-8869E22F03DD

Q34726376-DC4AE813-16F5-438D-AE3B-8EE214C064D1

P2860

Q34726376-046F1701-7142-4E04-AC38-59F1B1FB8EB4

Q34726376-074E92ED-AB62-4545-8B53-56301C197F5E

Q34726376-0E22CAAC-F5D4-4781-BA92-1F249067070C

Q34726376-3CBDF6DB-2E9D-4DCC-8DCE-92FBBCD88C18

Q34726376-3F0305F9-2EB0-49F5-AF74-A1EC4331D4F3

Q34726376-4D12D3F8-FBCF-4806-A3A0-06B942F0D5DE

Q34726376-51569C46-E009-4D5F-B6DB-5AF5A6991CB5

Q34726376-51982EE2-E7BF-4F3E-A7CF-B019D5D4E5AD

Q34726376-55F9D9D3-63E3-4A4F-98B1-3F7C0412F4D4

Q34726376-6937820F-F0BE-426D-9D1C-7A958033FA99

P2888

Q34726376-E73A845F-CA38-47FC-A971-A9F068EC9522

P304

Q34726376-70715AFB-4A58-42AE-B18E-35F1F49C3015

P31

Q34726376-B6B2659E-9157-48F1-897F-4459FEB8AD3B

P356

Q34726376-3775F11B-1E75-4E07-979D-5A4FC19874DB

P433

Q34726376-DEB1F809-C645-4A92-A7E3-9FF8220F1A28

P478

Q34726376-656F0BEE-E9BF-4C63-99D1-8BF32FCF2B92

P577

Q34726376-EE7BA795-343C-4BDA-9B53-ADFCFA7F6987

P5875

Q34726376-BC32EE61-2FFA-4F2E-9CEF-A9F63332F079

P6179

Q34726376-1F8ECA04-EBEC-4180-87DE-19B582624A0F

P698

Q34726376-9A19C803-A46D-405E-A660-408320089D57

P921

Q34726376-EC760117-6385-4EA1-8E4E-4A9AB8A72ACE

P932

Q34726376-9002FF04-C217-4628-A123-2F55575842B8

P356

S13300-014-0086-7

P1433

Diabetes Therapy

P1476

Dapagliflozin as monotherapy o ...... diabetes: an open-label study.

@en

P2093

Anna Maria Langkilde

http://www.w3.org/2001/XMLSchema#string

Arihiro Kiyosue

http://www.w3.org/2001/XMLSchema#string

Hiroshi Maegawa

http://www.w3.org/2001/XMLSchema#string

Jisin Yang

http://www.w3.org/2001/XMLSchema#string

Kohei Kaku

http://www.w3.org/2001/XMLSchema#string

Takuto Tokudome

http://www.w3.org/2001/XMLSchema#string

Yuji Hoshino

http://www.w3.org/2001/XMLSchema#string

Yukio Tanizawa

http://www.w3.org/2001/XMLSchema#string

Yumiko Ide

http://www.w3.org/2001/XMLSchema#string

P2860

Active sugar transport in health and disease

SGLT2 inhibition--a novel strategy for diabetes treatment.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.

Revised equations for estimated GFR from serum creatinine in Japan

P2888

s13300-014-0086-7

P304

415-433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-014-0086-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267731340

http://www.w3.org/2001/XMLSchema#string

P6179

1032123514

http://www.w3.org/2001/XMLSchema#string

P698

25341477

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4269643

http://www.w3.org/2001/XMLSchema#string